These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 27147385)
1. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study. Qureshi SA; Burch N; Druce M; Hattersley JG; Khan S; Gopalakrishnan K; Darby C; Wong JL; Davies L; Fletcher S; Shatwell W; Sothi S; Randeva HS; Dimitriadis GK; Weickert MO BMJ Open; 2016 May; 6(5):e010765. PubMed ID: 27147385 [TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules. Massironi S; Conte D; Rossi RE Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828 [TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Merola E; Panzuto F; Delle Fave G Oncotarget; 2017 Jul; 8(28):46624-46634. PubMed ID: 28402955 [TBL] [Abstract][Full Text] [Related]
4. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Arnold R; Simon B; Wied M Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693 [TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine tumours: an overview. Davies L; Weickert MO Br J Nurs; 2016 Feb 25-Mar 9; 25(4):S12-5. PubMed ID: 26911175 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558 [TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. Appetecchia M; Baldelli R J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864 [TBL] [Abstract][Full Text] [Related]
8. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Faiss S; Räth U; Mansmann U; Caird D; Clemens N; Riecken EO; Wiedenmann B Digestion; 1999; 60(5):469-76. PubMed ID: 10473972 [TBL] [Abstract][Full Text] [Related]
9. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours. Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373 [TBL] [Abstract][Full Text] [Related]
10. [Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours]. Uomo G; Germano D; Rabitti PG Minerva Endocrinol; 2001 Dec; 26(4):225-9. PubMed ID: 11782707 [TBL] [Abstract][Full Text] [Related]
11. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's). Oberg K Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941 [No Abstract] [Full Text] [Related]
12. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E; BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081 [TBL] [Abstract][Full Text] [Related]
13. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207 [TBL] [Abstract][Full Text] [Related]
14. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Chiti A; Fanti S; Savelli G; Romeo A; Bellanova B; Rodari M; van Graafeiland BJ; Monetti N; Bombardieri E Eur J Nucl Med; 1998 Oct; 25(10):1396-403. PubMed ID: 9818279 [TBL] [Abstract][Full Text] [Related]
15. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer]. Hofsli E Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977 [TBL] [Abstract][Full Text] [Related]
16. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study]. Bencsiková B Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781 [TBL] [Abstract][Full Text] [Related]
17. Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors. Laing E; Kiss N; Michael M; Krishnasamy M Neuroendocrinology; 2020; 110(5):430-442. PubMed ID: 31550712 [TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Öberg K; Lamberts SW Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899 [TBL] [Abstract][Full Text] [Related]
19. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Modlin IM; Pavel M; Kidd M; Gustafsson BI Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567 [TBL] [Abstract][Full Text] [Related]
20. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Toumpanakis C; Caplin ME Semin Oncol; 2013 Feb; 40(1):56-68. PubMed ID: 23391113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]